Category Archives: Hepatitis C care & treatment

Epclusa receives FDA approval for treating HCV in HIV/HCV co-infected persons

On August 1, 2017 the Food and Drug Administration (FDA) updated the approval for the Gilead HCV medication sofosbuvir/velpatasvir (400mg/100mg), brand name “Epclusa” to include HIV/HCV coinfection. This single tablet medication comprises sofosbuvir (SOF), a nucleotide polymerase inhibitor, and velpatasvir (VEL), an NS5A inhibitor, and is…Read More

July 28 is World Hepatitis Day: Eliminate Hepatitis

July 28, 2017 is World Hepatitis Day, one of only four disease-specific days recognized by the World Health Organization. Around the world and around the United States organizations and individuals come together on this day to raise awareness of the global burden of viral hepatitis and…Read More

Vosevi: Frequently Asked Questions

On July 18, 2017 the Food and Drug Administration (FDA) approved Gilead’s HCV medication sofosbuvir/velpatasvir/voxilaprevir (400mg/100mg/100mg), brand name “Vosevi” for the re-treatment of HCV in treatment-experienced people. This single tablet medication comprises sofosbuvir (SOF), a nucleotide polymerase inhibitor, velpatasvir (VEL), an NS5A inhibitor, and voxilaprevir (VOX),…Read More

Project Inform releases new report on safer consumption spaces in the U.S.

SAFER CONSUMPTION SPACES IN THE UNITED STATES: The time is right to unite for a national movement Click here for a PDF of the Report. Project Inform is pleased to release “Safer Consumption Spaces in the United States: Uniting for a National Movement.” This report stems…Read More

Working at the State Level: Project Inform’s California Advocacy for 2017

State-level advocacy efforts are crucial to create lasting change. Often efforts that are started at local and state levels inform national trends and structural changes at the federal level (think about the history of same-sex marriage, health care reform, and syringe exchange in the United States)….Read More

CROI 2017: New two-drug maintenance regimen continues to suppress HIV over 144 weeks

At the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), results from the LATTE study showed that the 2-drug regimen of the integrase inhibitor cabotegravir (CAB) + the NNRTI rilpirivine (RPV, Edurant) suppressed HIV levels as well as a 3-drug efavirenz (Sustiva) regimen through 144 weeks….Read More

CROI 2017: Ibalizumab is effective at reducing HIV viral load in people with few treatment options

In a late-breaker presentation at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), a new monoclonal antibody drug called ibalizumab reduced viral loads in individuals with multi-drug resistant HIV. The results showed that adding the drug to a failing regimen may help treatment-experienced people who…Read More